

CRC

**CYTOLYTIC
LYMPHOCYTES
and
COMPLEMENT:
EFFECTORS
of the
IMMUNE SYSTEM**
Volume I

Eckhard R. Podack

CRC PRESS

Cytolytic Lymphocytes and Complement: Effectors of the Immune System

Volume I

NOT FOR SALE

Editor

Eckhard R. Podack, M.D.

Professor of Microbiology and Immunology
and

Professor of Medicine
New York Medical College
Valhalla, New York

Current address:

Professor

Department of Microbiology and Immunology
University of Miami School of Medicine
Miami, Florida



CRC Press, Inc.
Boca Raton, Florida

Library of Congress Cataloging-in-Publication Data

Cytolytic lymphocytes and complement

Includes bibliographies and index.

1. T cells. 2. Killer cells. 3. Complement
(Immunology) I. Podack, Eckhard R. [DNLM: 1. Complement
--immunology. 2. Cytotoxicity, Immunologic. 3. Killer
Cells, Natural--immunology. 4. T Lymphocytes,
Cytotoxic--immunology. QW 568 C997]
QR185.8.T2C98 1988 616.07'9 87-22431

ISBN 0-8493-6968-1 (v. 1)

ISBN 0-8493-6969-X (v. 2)

This book represents information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Every reasonable effort has been made to give reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use.

All rights reserved. This book, or any parts thereof, may not be reproduced in any form without written consent from the publisher.


Direct all inquiries to CRC Press, Inc., 2000 Corporate Blvd., N.W., Boca Raton, Florida, 33431.

© 1988 by CRC Press, Inc.

International Standard Book Number 0-8493-6968-1 (Volume I)
International Standard Book Number 0-8493-6969-X (Volume II)
Library of Congress Card Number 87-22431
Printed in the United States

Dedication

To my father, Dr. med. Waldemar W. Podack,
in gratitude for stimulating my interest in science.



INTRODUCTION

These volumes, *Cytolytic Lymphocytes and Complement: Effectors of the Immune System*, originate from the realization that pathways of recognition and killing of foreign targets follow similar routes in the humoral and cellular part of the immune system. In particular, the homology of immunoglobulins with the T-cell-MHC-antigen receptor at the beginning of the recognition sequence and the homology of complement component C9 with lymphocyte perforin 1 (P1) as pore formers at the end of the effector sequence are striking examples.

From my own point of view, the catalyst for suspecting mechanistically similar pathways in the effector systems of complement and cytolytic lymphocytes derived from the discovery of the polymerization of C9 to the circular structure of poly C9 (see Figure 1), which is responsible for the well-known ultrastructural complement lesions described originally in 1964. This simple finding immediately clarified conceptually the mechanisms for the formation of transmembrane pores both by complement and by cytolytic T- and NK-cells.

The motivation to assemble these volumes through the contributions of outstanding investigators in complement and lymphocyte research thus was, and is, to increase the awareness that mechanisms and molecular models studied in one system may well be of relevance to the other. Since complement has been studied in detail in all of its aspects, including activation, host protection, cytolysis, and repair mechanisms, it can serve as a guiding model system for the investigator of cellular mechanisms.

Effector cells, on the other hand, have the facility to interact with targets through surface membrane receptors allowing them an additional degree of complexity compared to humoral systems. This complexity, combined with the subcellular organization of cells (for example, the sequestration of cytolytic proteins in granules), offers alternatives for the mediation and regulation of cellular pathways that can be quite different from the humoral pathway.

Owing to these differences, the approaches to the use of the two effector systems for immune therapy are quite distinct. However, both are being explored at this time, and only future work will tell which combination of immune therapy will be most effective.

It is one of the most fascinating aspects of research to experience the development of common concepts with the attendant simplifications and understanding at the molecular level of previously poorly understood phenomena. It is hoped that this book will contribute to this process.

E. R. Podack




FIGURE 1. Poly C9.



THE EDITOR

Eckhard R. Podack, M. D., was appointed Full Professor of Microbiology and Immunology at the University of Miami School of Medicine in 1987. Prior to this appointment, he had been Professor of Medicine, Microbiology, and Immunology at the New York Medical College in Valhalla, New York, since 1984. From 1974 to 1984, he was associated with the Department of Immunology at the Research Institute of Scripps Clinic in La Jolla, California.

Dr. Podack holds the M.D. from Johann-Wolfgang-Goethe University in Frankfurt, Germany, and wrote his dissertation in Biochemistry at the Georg August University of Göttingen in Germany. His research thesis was honored with the Annual Award by the German Diabetes Society in 1973. Post-doctoral fellowship training was completed in the Department of Biochemistry at the University of Göttingen before he moved to this country in 1974. In biochemistry and immunology, Dr. Podack is internationally recognized and is a frequent invited lecturer to universities in Europe and the United States.

After collaborating with Hans Müller-Eberhard at the Scripps Research Foundation from 1974 to 1978 on complement components and activation, he spent the next six to eight years studying independently the molecular biology of molecules that cytotoxic lymphocytes use to kill their targets.

Dr. Podack is the recipient of two National Institutes of Health grants, an American Cancer Society grant, two Fellowship grants for his Post-Doctoral fellows, and a proposal of studies from private industry.

Dr. Podack is Associate Editor of the *Journal of Immunology* and Ad Hoc Reviewer for nine additional scientific journals. He reviews grant applications for the Veterans Administration, the National Science Foundation, the Fogarty International Fellowship Center, and the National Institutes of Health.

CONTRIBUTORS, VOLUME I

M. Amin Arnaut

Department of Pediatrics
Children's Hospital
Boston, Massachusetts

Barbara A. Benson

Research Service
VA Medical Center
Minneapolis, Minnesota

Gideon Berke

Department of Cell Biology
Weizmann Institute of Science
Rehovot, Israel

Steven J. Burakoff

Department of Pediatrics
Dana-Farber Cancer Institute
Boston, Massachusetts

David F. Carney

Department of Pathology
University of Maryland
Baltimore, Maryland

Zanvil A. Cohn

The Rockefeller University
New York, New York

Neil R. Cooper

Department of Molecular Immunology
Scripps Clinic and Research Foundation
La Jolla, California

Agustin P. Dalmaso

Laboratory Service
VA Medical Center
Minneapolis, Minnesota

Gunther Dennert

Department of Microbiology
University of Southern California
Los Angeles, California

Julia L. Greenstein

Department of Pediatric Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Zvi Keren

Department of Cell Biology
Weizmann Institute of Science
Rehovot, Israel

M. Edward Medof

Department of Pathology and Medicine
Case Western Reserve University
Cleveland, Ohio

Steven J. Mentzer

Department of Pediatric Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Michael K. Pangburn

Department of Biochemistry
University of Texas Health Center
Tyler, Texas

Eckhard R. Podack

Department of Microbiology
and Immunology
University of Miami
School of Medicine
Miami, Florida

David H. Raulet

Center for Cancer Research and
Department of Biology
Massachusetts Institute of Technology
Cambridge, Massachusetts

Verne N. Schumaker

Molecular Biology Institute
University of California, Los Angeles
Los Angeles, California

Moon L. Shin

Department of Pathology
University of Maryland
Baltimore, Maryland

Jürg Tschopp

Institute of Biochemistry
University of Lausanne
Epalinges-sur-Lausanne, Switzerland

John Ding-E. Young

Cell Physiology and Immunology
Laboratory
Rockefeller University
New York, New York

Robert J. Ziccardi

Department of Molecular Immunology
Scripps Clinic and Research Foundation
La Jolla, California

CONTRIBUTORS, VOLUME II**Bharat B. Aggarwal**

Department of Molecular Biology
and Immunology
Genentech, Inc.
South San Francisco, California

Ramani A. Aiyer

Department of Molecular Biology
and Immunology
Genentech, Inc.
South San Francisco, California

Michael J. Bevan

Department of Immunology
Scripps Clinic and Research Foundation
La Jolla, California

Benjamin Bonavida

Department of Microbiology and
Immunology
School of Medicine
University of California, Los Angeles
Los Angeles, California

Thomas J. Braciale

Department of Pathology
Washington University School of
Medicine
St. Louis, Missouri

Vivian Lam Braciale

Department of Pathology
Washington University
School of Medicine
St. Louis, Missouri

Jen W. Chiao

Department of Medicine
New York Medical College
Valhalla, New York

John J. Cohen

Department of Microbiology and
Immunology
University of Colorado Medical School
Denver, Colorado

Zanvil A. Cohn

The Rockefeller University
New York, New York

Gunther Dennert

Department of Microbiology
University of Southern California
Los Angeles, California

Richard C. Duke

Department of Microbiology
and Immunology
University of Colorado Medical School
Denver, Colorado

Brett T. Gemlo

Department of Surgery
University of California
San Francisco, California

Elizabeth Ann Grimm

Departments of Tumor Biology
and General Surgery
University of Texas System Cancer
Center

M. D. Anderson Hospital
Houston, Texas

Hans Hengartner

Department of Experimental Pathology
Institute of Pathology
Zurich, Switzerland

Frederick C. Kull, Jr.

Wellcome Research Laboratories
Research Triangle Park
North Carolina

Lewis L. Lanier

Research and Development Department
B.D. Monoclonal Center
Mountain View, California

Leo Lefrancois

Department of Immunology
Scripps Clinic and Research Foundation
La Jolla, California

Ben-Yao Lin

Department of Microbiology
New York Medical College
Valhalla, New York

Aron Lukacher

Department of Pathology
Washington University School of
Medicine
St. Louis, Missouri

Abraham Mittelman

Division of Neoplastic Disease
New York Medical College
Valhalla, New York

Warren W. Myers

Department of Research
Becton Dickinson
Mt. View, California

Carl F. Nathan

Cornell Medical College
New York Hospital
New York, New York

Kristin Penichet

Department of Microbiology and
Immunology
New York Medical College
Valhalla, New York

Joseph H. Phillips

Department of Research and Development
Becton Dickinson
Mt. View, California

Eckhard R. Podack

Department of Microbiology
and Immunology
University of Miami
School of Medicine
Miami, Florida

Anthony A. Rayner

Department of Surgery
University of California
San Francisco, California

Nancy H. Ruddle

Department of Epidemiology
and Public Health
Yale University Medical School
New Haven, Connecticut

Donald Scott Schmid

Division of Viral Diseases
Centers for Disease Control
Atlanta, Georgia

Uwe D. Staerz

Basel Institute for Immunology
Basel Switzerland

Marianne T. Sweetser

Department of Pathology
Washington University School of
Medicine
St. Louis, Missouri

Carl-Wilhelm Vogel

Department of Biochemistry and
Medicine, and Vincent T. Lombardi
Cancer Center
Georgetown University
Washington, D.C.

Susan C. Wright

Department of Microbiology and
Immunology
UCLA School of Medicine
Los Angeles, California

John Ding-E. Young

Cell Physiology and Immunology
Laboratory
Rockefeller University
New York, New York

TABLE OF CONTENTS, VOLUME I

Section I.A: Recognition — Complement

Chapter 1

C1 Structure and Antibody Recognition 3

V. N. Schumaker

Chapter 2

Activation of C1 and the Classical Pathway of Complement 21

R. J. Ziccardi and N. R. Cooper

Chapter 3

Initiation and Activation of the Alternative Pathway of Complement 41

M. K. Pangburn

Chapter 4

Decay Accelerating Factor and the Defect of Paroxysmal Nocturnal Hemoglobinuria 57

M. Edward Medof

Section I.B: Recognition — Killer Lymphocytes

Chapter 5

T Cell Specificity and the T Cell Receptor α , β , and γ Chains 89

D. H. Raulet

Chapter 6

Structure and Function of a Family of Leukocyte Adhesion Molecules (LEU-CAM) Involved in T Cell Killing and Complement Mediated Phagocytosis 109

M. A. Arnaout

Chapter 7

The Role of Accessory Molecules in T Cell Recognition 127

J. L. Greenstein, S. J. Mentzer, and S. J. Burakoff

Chapter 8

Toward Understanding Target Binding and Lysis by Natural Killer Cells 143

G. Dennert

Chapter 9

The Homology between Specific- and Nonspecific-Lectin or Oxidation Dependent CTL/Target Interactions 155

G. Berke and Z. Keren

Section II.A: Cytolytic Mechanism — Complement

Chapter 10

Assembly and Structure of the Membrane Attack (MAC) of Complement 173

E. R. Podack

| | |
|--|-----|
| Chapter 11 | |
| Structure and Function of C9 and Poly C9 | 185 |
| J. Tschopp and E. R. Podack | |
| Chapter 12 | |
| Pore Size of Lesions Induced by Complement on Red Cell Membranes and Its Relation to C5b-8, C5b-9, and Poly C9 | 207 |
| A. P. Dalmasso and B. A. Benson | |
| Chapter 13 | |
| Pore Size and Functional Properties of Defined MAC and Poly C9 Complexes: Reconstitution into Model Lipid Membranes | 221 |
| J. Ding-E Young, Z. A. Cohn, and E. R. Podack | |
| Chapter 14 | |
| Mechanisms of the Cellular Defense Response of Nucleated Cells to Membrane Attack by Complement | 229 |
| M. L. Shin and D. F. Carney | |
| Index | 253 |

TABLE OF CONTENTS, VOLUME II

Section II.B: Cytolytic Mechanism — Killer Lymphocytes

| | |
|---|----|
| Chapter 15 | |
| Properties and Function of Cytolytic Lymphocyte Granules | 3 |
| E. R. Podack | |
| Chapter 16 | |
| Properties of Transmembrane Channels Induced by Cytolytic Lymphocytes..... | 19 |
| J. Ding-E. Young, E. R. Podack, C. Nathan, H. Hengartner, and Z. A. Cohn | |
| Chapter 17 | |
| The Role of Nuclear Damage in Lysis of Target Cells by Cytotoxic T Lymphocytes | 35 |
| R. C. Duke and J. J. Cohen | |

Section II.C: Soluble Cytotoxic Factors Produced by Lymphocytes

| | |
|--|----|
| Chapter 18 | |
| Production and Function of Lymphotoxin Secreted by Cytolytic T Cells | 61 |
| D. S. Schmid and N. H. Ruddle | |
| Chapter 19 | |
| Tumor Necrosis Factor/Cachectin | 75 |
| F. C. Kull, Jr. | |

| | |
|--|----|
| Chapter 20 | |
| Natural Killer Cytotoxic Factor (NKCF) as Mediator in the Lytic Pathway of NK Cell Mediated Cytotoxicity | 91 |
| B. Bonavida and S. C. Wright | |

| | |
|--|-----|
| Chapter 21 | |
| Tumor Necrosis Factors | 105 |
| R. A. Aiyyer and B. B. Aggarwal | |

Section III. Therapeutic Applications

| | |
|--|-----|
| Chapter 22 | |
| Antibody Conjugates with Cobra Venom Factor as Selective Agents for Tumor Cell Killing | 135 |
| C.-W. Vogel | |

| | |
|--|-----|
| Chapter 23 | |
| A Function for NK Cells in Acute Bone Marrow Allograft Rejection | 153 |
| G. Dennert | |

| | |
|---|-----|
| Chapter 24 | |
| Cytolytic T Lymphocyte Clones in Anti-Viral Immunity: Effector Function In Vivo and Mechanism of Action | 161 |
| T. J. Braciale, A. E. Lukacher, M. T. Sweetser, and V. L. Braciale | |

| | |
|---|-----|
| Chapter 25 | |
| Interleukin-2 Activated Cytotoxic Lymphocytes (LAK cells) as Antigen Nonspecific Amplifiers of the Immune Response: General Characteristics and Considerations for Cancer Therapy | 175 |
| E. A. Grimm | |

| | |
|---|-----|
| Chapter 26 | |
| The Contribution of Natural Killer and T-Cells to the Lymphokine Activated Killer Cell Phenomenon | 193 |
| J. H. Phillips, B. T. Gemlo, W. W. Myers, A. A. Rayner, and L. L. Lanier | |

| | |
|--|-----|
| Chapter 27 | |
| Targeting for T-Lymphocyte-Mediated Lysis by Hybrid Antibodies | 205 |
| U. D. Staerz, L. Lefrancois, and M. J. Bevan | |

| | |
|--|-----|
| Chapter 28 | |
| Longterm Growth and Expansion of I12 Activated NK-Cells for Cancer Therapy | 219 |
| E. R. Podack, K. O. Penichet, B. Y. Lin, J. W. Chiao, and A. Mittelman | |

| | |
|-------------|-----|
| Index | 227 |
|-------------|-----|

CI STRUCTURE AND ANTIBODY RECOGNITION

Ying Ni, Shanghai

TABLE OF CONTENTS

I. Introduction 1

II. Molecular Architecture of CI and Complement 1

III. Structure of C1 1

Section I.A: Recognition — Complement

IV. Structure of C1 1

V. Structure of C1 Inhibitor 1

VI. Antibody Recognition by C1q and C1r 1

VII. A Proposed Model for the Control of Complement Activation 1

VIII. Summary 1

IX. Acknowledgments 1

X. References 1



Section 1. A. Recognition of the fact that the...
 B. The...
 C. The...
 D. The...
 E. The...

Section 1. A. Recognition of the fact that the...

Chapter 1. The...
 Chapter 2. The...
 Chapter 3. The...
 Chapter 4. The...
 Chapter 5. The...

Chapter 6. The...
 Chapter 7. The...
 Chapter 8. The...
 Chapter 9. The...
 Chapter 10. The...

Chapter 11. The...
 Chapter 12. The...
 Chapter 13. The...
 Chapter 14. The...
 Chapter 15. The...

Chapter 1

C1 STRUCTURE AND ANTIBODY RECOGNITION

Verne N. Schumaker



TABLE OF CONTENTS

| | | |
|-------|---|----|
| I. | Introduction | 4 |
| II. | Multivalent Attachment of C1 to a Cluster of Antibody Fc Initiates the Classical Complement Pathway | 4 |
| III. | Structure of C1q | 5 |
| IV. | Structures of C1r and C1s | 7 |
| V. | Structures of C1r ₂ C1s ₂ | 9 |
| VI. | Structure of C1 | 9 |
| VII. | Structure of C1-Inhibitor | 11 |
| VIII. | Antibody Recognition by C1q and C1 | 11 |
| IX. | A Hypothetical Model for the Complex Formed Between C1 and C1-Inhibitor and its Possible Role in the Activation of Complement | 13 |
| X. | Summary | 15 |
| XI. | Acknowledgments | 15 |
| | References | 16 |

I. INTRODUCTION

This chapter will focus upon the remarkable structure of the first component of complement, C1, and upon its interactions with C1-inhibitor and with antibody. A comprehensive review of C1 has just appeared;¹⁷ therefore, we will concentrate on experimental studies published after the writing of that review and a hypothetical, but particularly satisfying, model for the structure of C1, variants of which have been proposed by three different laboratories.

Reviews which discuss the early components of the classical pathway, especially C1 and C1q, have been written by Cooper,¹⁷ Lachmann and Hughes-Jones,⁴⁴ Colomb et al.,^{15,16} Ziccardi,⁹⁴ Reid,⁶⁶ Loos,⁴⁷ and Porter and Reid,^{61,67} among others.

The destruction and elimination of bacteria, virus, and toxins by the humoral arm of the immune system involves antibody molecules, phagocytic cells, and the alternate and classical pathways as well as the membrane attack complex of complement.^{43,50} Activation of either complement pathway results in the release of anaphylatoxic peptides causing increased vascular permeability, smooth muscle contraction, release of histamine from mast cells, and chemotaxis of phagocytes to the site of infection;^{34,35} as well as the deposition of potent opsonins such as C3b^{54,99} and activation of the terminal components which assemble to mount a direct attack on the membrane of the invader^{7,51} (and see Chapter 10, this volume).

Immune complexes composed of IgM and IgG as well as certain bacterial and viral cell wall materials, are included among the strong activators of the classical pathway. Individuals deficient in the early components of the classical pathway, C1q, C1r, C2 and C4, are only occasionally more vulnerable to bacterial and viral infection;¹ presumably, the alternate pathway can usually provide the critical defense effector functions, as it must prior to the development of effective levels of antibody in a naive host. Deficient individuals appear to be susceptible to immune-complex-associated renal diseases;^{12,26,80} thus, the early components may play an important role in the solubilization and elimination of immune complexes.

The key role of immune complex recognition and initiation of the classical pathway is the principle function of the first component of complement. We will begin with an overview to illustrate the probable structures of the macromolecules involved, the names of some of their component parts, and what is meant by the "recognition" and "initiation" processes.

II. MULTIVALENT ATTACHMENT OF C1 TO A CLUSTER OF ANTIBODY Fc INITIATES THE CLASSICAL COMPLEMENT PATHWAY

Immune complex recognition is accomplished by the binding of C1 to a cluster of antibody Fc, as schematically illustrated in Figure 1, and its subsequent activation.^{71,98} C1 is a complex composed of five protein subcomponents: one C1q, two C1r and two C1s.⁸⁹ The C1q subcomponent is a fascinating macromolecule, consisting of a central "stem" with six branching "arms", each arm terminating in a globular C1q "head".⁶¹ The heads bind to complementary regions on the Fc domains of IgG and IgM. Since the binding of a single head to a single Fc is weak, tight binding of C1q to an immune complex requires multivalent attachment to a cluster of Fc, as illustrated in Figure 1.^{98,106}

Binding of C1 to immune complexes is usually followed by a slower activation step in which most of the bound C1 becomes proteolytically active. Activation involves the other subcomponents; the two C1r and two C1s subcomponents are shown in Figure 1 as a string of balls wound among the C1q arms. C1r and C1s are proenzymes, and activation involves proteolytic cleavage of the C1r polypeptide. The activated C1r then cleaves C1s which, in turn, cleaves the next components in the classical pathway, C4 and C2, to initiate the classical component cascade.⁸⁶

Not only can C1 activate by binding multivalently to an immune complex, but also C1